Label changes for sleep meds with zolpidem obtain FDA nod

05/14/2013 | Reuters

Label changes, including lower doses for sleep treatments with zolpidem, a drug that affects the mental alertness of patients even a day after its intake, were approved by the FDA. Driving and other activities that require complete mental alertness the following day should be avoided by patients who receive zolpidem extended-release medications, the agency said. The approval covered label changes for Sanofi's Ambien and Ambien CR, as well as Meda's Edluar.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC